| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
hMAO-B (human monoamine oxidase B).
|
|---|---|
| ln Vitro |
hMAO-B-IN-5 is a potent hMAO-B inhibitor with an IC50 of 0.12 μM (120 nM). It also exhibits a Ki of 33 nM. This high potency, combined with its reversibility and selectivity, makes it a valuable tool for studying hMAO-B function and its role in CNS disorders.
|
| ln Vivo |
The compound's ability to cross the blood-brain barrier makes it suitable for in vivo studies targeting the CNS. Its neuroprotective effects have been observed in cellular models, suggesting that it may protect neurons from oxidative stress and other pathological processes associated with neurodegenerative diseases.
|
| Enzyme Assay |
In vitro enzyme assays are performed to determine the inhibitory activity of hMAO-B-IN-5 against hMAO-B. The enzyme is incubated with a substrate (e.g., kynuramine) and varying concentrations of the compound. The inhibition of enzyme activity is measured, and the IC50 and Ki values are calculated from the data.
|
| Cell Assay |
Cells expressing hMAO-B (e.g., SH-SY5Y neuroblastoma cells) are treated with hMAO-B-IN-5 to assess its cellular effects. The compound's ability to inhibit hMAO-B activity in intact cells is measured by monitoring the metabolism of monoamine substrates. Its neuroprotective effects against oxidative stress and other insults are also evaluated.
|
| Animal Protocol |
In vivo studies are conducted in animal models of neurodegenerative diseases, such as the MPTP-induced Parkinson's disease model, to evaluate the therapeutic potential of hMAO-B-IN-5. The compound is typically administered via oral or intraperitoneal routes, taking advantage of its BBB penetration. Its effects on motor function, neurochemical markers, and neuropathology are assessed.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data are publicly available for hMAO-B-IN-5. However, its classification as a BBB-penetrant compound suggests favorable properties for CNS exposure. Standard PK studies would be conducted to determine its bioavailability, half-life, and brain-to-plasma ratio.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available. However, its low toxicity has been noted in cell-based studies. As a reversible and selective inhibitor, it may have a more favorable safety profile compared to irreversible inhibitors. Standard toxicology studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
hMAO-B-IN-5 is a promising research compound for the study and potential treatment of Parkinson's disease and other neurodegenerative disorders. Its potent, selective, and reversible inhibition of hMAO-B, combined with its BBB penetration, makes it a valuable tool. It is not approved for clinical use and is currently for research purposes only.
|
| Molecular Formula |
C24H22O3
|
|---|---|
| Molecular Weight |
358.429687023163
|
| Exact Mass |
358.156
|
| CAS # |
358343-63-2
|
| PubChem CID |
5346401
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.5
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
27
|
| Complexity |
450
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C1C=CC(/C=C/C(C2C=CC(=CC=2)OCC)=O)=CC=1)CC1C=CC=CC=1
|
| InChi Key |
DZBMIWJIJRIBEG-LICLKQGHSA-N
|
| InChi Code |
InChI=1S/C24H22O3/c1-2-26-22-15-11-21(12-16-22)24(25)17-10-19-8-13-23(14-9-19)27-18-20-6-4-3-5-7-20/h3-17H,2,18H2,1H3/b17-10+
|
| Chemical Name |
(E)-1-(4-ethoxyphenyl)-3-(4-phenylmethoxyphenyl)prop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7899 mL | 13.9497 mL | 27.8995 mL | |
| 5 mM | 0.5580 mL | 2.7899 mL | 5.5799 mL | |
| 10 mM | 0.2790 mL | 1.3950 mL | 2.7899 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
